Banning WuXi is more complicated than it might sound

A bill moving through Congress is meant to effectively ban certain Chinese life sciences companies from doing business in the U.S., thereby preserving the competitive advantage of American drug manufacturers. But actually going through with it risks seriously hobbling the companies it’s purported to help.

Among the Chinese firms in Congress’ crosshairs is WuXi AppTec, a contractor that gets more than half of its revenue from U.S. companies.